Immunis Inc., a trailblazer in secretome therapeutics for age-related diseases and immune dysfunction, is proud to announce its remarkable double-win from the 2024 Global Health and Pharma (GHP) awards. The company has been honored with two prestigious awards: “Innovation Award in Age-Related Disease R&D” and “Immune Dysfunction Treatment Developers of the Year.” These accolades represent the company’s dedication to pioneering solutions for some of the most challenging age-related health concerns including muscle atrophy and metabolic decline.

The GHP awards are recognized internationally as a benchmark for excellence in the healthcare and pharmaceutical industries. The “Innovation Award in Age-Related Disease R&D” acknowledges our cutting-edge secretome research and development of IMMUNA in an effort to reverse multiple aspects of aging. Simultaneously, the “Immune Dysfunction Treatment Developers of the Year” award celebrates our groundbreaking advancements in secretome therapies designed to combat immune dysfunction, the root cause of age-related disease. These awards are a tribute to our relentless pursuit of transformative healthcare solutions.

“Our double win at this year’s GHP awards is an incredible honor and a reflection of our team’s hard work and commitment to improving the way humans age,” said Joelle Hafen, Director of Operations at Immunis. “These awards inspire us to continue pushing the boundaries of what’s possible in biotechnology and we aim to develop therapies that enable a healthier future for all.”

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com